In ovarian cancer models, genetic deletion or pharmacological blockade of C5aR1 led to reduced endothelial cell activation and impaired neovascularization, while activation of C3aR and C5aR1 on immune and stromal cells stimulated angiogenesis through VEGF-dependent pathways (148). Here, C5AR1 is linked to ovarian cancer.